$300 for a bottle of eye drops. That’s not unusual — and it’s one of the sharper sticker shocks in vision care. Prescription eye drops range from generic glaucoma medications at $15–$30 to branded inflammatory and dry eye drops that routinely exceed $200–$400 per month without insurance. Understanding what drives that spread helps you ask the right questions and identify where savings are actually available.
What Different Prescription Eye Drops Cost
The category of drop matters enormously. Generic availability, brand exclusivity, and whether there’s a therapeutic alternative all affect price.
| Drop Type | Generic Cost | Brand-Name Cost | Notes |
|---|---|---|---|
| Glaucoma (prostaglandin analogs) | $15–$45/bottle | $150–$300/bottle | Generic latanoprost widely available |
| Glaucoma (beta-blockers) | $10–$30/bottle | $80–$150/bottle | Timolol generic is low-cost |
| Dry eye (cyclosporine, Restasis) | N/A | $200–$400/month | No generic as of 2026 |
| Dry eye (lifitegrast, Xiidra) | N/A | $500–$600/month | No generic |
| Dry eye (Tyrvaya, nasal spray) | N/A | $250–$350/month | Newer option, limited insurance |
| Antibiotic drops (infections) | $15–$50/bottle | $80–$200/bottle | Generic options for most |
| Steroid drops (post-op) | $20–$60/bottle | $100–$200/bottle | Prednisolone generic available |
| Allergy drops (antihistamine) | $20–$60/bottle | $80–$150/bottle | Olopatadine generic available |
Glaucoma Drops: The Generic Story
Glaucoma is the leading cause of irreversible blindness in the US, and the NEI estimates that more than 3 million Americans have glaucoma — with another 2.7 million undiagnosed. Most glaucoma treatment starts with daily eye drops to reduce intraocular pressure. The good news: generic versions of the most commonly prescribed classes (prostaglandin analogs like latanoprost, beta-blockers like timolol) are widely available and cost $10–$45 per bottle.
Branded combination drops (Combigan, Cosopt, Rocklatan) cost significantly more and aren’t always covered by insurance at the same tier as generics. If you’re prescribed a branded glaucoma drop, ask specifically: “Is there a generic for this, or a generic equivalent from a different drug class I could try first?”
The AOA emphasizes that adherence to glaucoma medication is the single biggest predictor of disease control — and cost is one of the main reasons patients skip doses or stop refilling. If cost is affecting your adherence, tell your ophthalmologist. There are almost always lower-cost therapeutic options to explore.
Several strategies work well, sometimes dramatically:
GoodRx and pharmacy discount cards: For generic glaucoma and antibiotic drops, GoodRx often brings the cash price below your insurance copay. Check before you fill.
Manufacturer savings programs: Allergan (Restasis), Shire (Xiidra), and others offer copay assistance cards that cap out-of-pocket cost for commercially insured patients — often at $0–$25/month. These programs don’t apply to Medicare or Medicaid.
Medicare Extra Help (LIS): For Medicare beneficiaries who qualify based on income, the Low Income Subsidy program reduces Part D prescription costs substantially — often to $3–$10 copays.
Authorized generics and 90-day supply: Ordering a 90-day supply through mail-order pharmacy typically saves 20–30% vs. 30-day fills. Ask your ophthalmologist to write the prescription as a 90-day supply.
Therapeutic alternatives: Ask your prescriber whether an older, off-patent drop in the same class would work for your specific situation. This is especially relevant for glaucoma, where multiple drug classes exist and several have cheap generics.
Dry Eye Prescription Drops: The Expensive Exception
Restasis (cyclosporine 0.05%) and Xiidra (lifitegrast 5%) are the two primary prescription treatments for chronic dry eye disease — and both remain branded with no generic available. That puts them in the $200–$600/month range without insurance or manufacturer assistance.
Coverage varies widely by plan. Many insurance formularies place these in Tier 3 or Tier 4, meaning copays of $50–$150/month even with coverage. Medicare Part D coverage depends on your specific plan’s formulary. Manufacturer savings cards (for commercially insured patients) can bring Restasis to $25–$50/month and Xiidra to $0–$25/month.
If you’re on Medicare and have a documented dry eye disease diagnosis, ask your ophthalmologist whether punctal plugs or other in-office treatments might reduce your dependence on prescription drops. Punctal plugs cost $50–$300 total and are covered by Medicare — and they eliminate the monthly drop expense entirely for some patients.
Don’t substitute OTC artificial tears for prescribed immunomodulatory drops (Restasis, Xiidra) on your own. OTC lubricants manage symptoms; prescription drops treat the underlying inflammatory condition. If cost is making you skip fills, talk to your prescriber about manufacturer assistance programs or coverage alternatives before stopping treatment. Inadequately treated chronic dry eye can cause corneal damage over time.
Post-Operative and Short-Term Drops
After eye surgery (LASIK, cataract surgery, pterygium removal), you’ll typically be prescribed a course of antibiotic and steroid drops for 4–8 weeks. These are finite-course prescriptions — not indefinite monthly expenses. Generic versions of prednisolone acetate and common antibiotic drops are available and significantly cheaper than branded alternatives.
If your surgical package includes post-op medications, ask specifically which drops are included. Some practices include them; others expect you to fill separate prescriptions. Budget $50–$150 for a full post-operative drop course if it’s not bundled.
Bottom Line
Prescription eye drop costs range from under $20 for generic glaucoma medications to $500+/month for branded dry eye treatments without assistance. For glaucoma medications, always ask about generics first. For branded chronic dry eye treatments, manufacturer savings programs and pharmacy discount cards can dramatically reduce cost. If eye drop costs are affecting whether you fill your prescription, that’s a conversation to have with your prescriber — not a problem to solve by stopping treatment.